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RESEARCH ARTICLE Open Access
Secondary prevention after ischaemic
stroke: the ASPIRE-S study
Linda Brewer1*, Lisa Mellon2, Patricia Hall2, Eamon Dolan3, Frances Horgan4, Emer Shelley5, Anne Hickey2,
David Williams1, on behalf of the ASPIRE-S Study Group
Abstract
Background: Survivors of ischaemic stroke (IS) are at high-risk for future vascular events. Comprehensive
information on the adequacy of secondary prevention after IS is lacking despite the knowledge that appropriate
secondary prevention improves long-term patient outcomes. ASPIRE-S (Action on Secondary Prevention Interventions
and Rehabilitation in Stroke) aimed to prospectively assess secondary prevention in patients 6 months following IS.
Methods: Consenting patients admitted with IS to three Dublin hospitals were recruited over 1 year, from October
2011. At 6 months post IS a comprehensive assessment was completed, modelled on the EUROASPIRE protocol for
evaluation of the adequacy of secondary prevention in post-discharge cardiac patients. This assessment included
measurements of blood pressure, body mass index and fasting lipid and glucose profiles. Secondary preventive
medications and smoking status were also documented.
Results: Three hundred two patients (58 % male) participated, of whom 256 (85 %) were followed-up at 6 months.
Mean age was 69 years (range 22–95). At follow-up, 68 % of patients had a BMI >25 kg/m2 and 16.4 % were still
smoking. Almost two-thirds (63.4 %) had a blood pressure >140/90 and 23 % had low-density-lipoprotein >2.5 mmol/L.
28 % of diabetic patients had HbA1c ≥7 %. Ninety seven percent of patients were on anti-platelet and/or anticoagulant
therapy. Of those with atrial fibrillation, 82 % were anti-coagulated (mean INR of 2.4). Ninety-five percent were on
lipid-lowering therapy and three-quarters were on anti-hypertensive therapy.
Conclusion: This prospective multi-centre survey of IS patients demonstrated a high prevalence of remaining
modifiable risk factors at 6 months post stroke, despite the widespread prescription of secondary preventive
medications. There is scope to improve preventive measures after IS (in particular blood pressure) by incorporating
evidence-based guidelines into quality assurance cycles in stroke care.
Keywords: Ischaemic stroke, Secondary prevention, Risk factors
Background
Stroke is a leading cause of death and disability resulting
in substantial personal and healthcare costs. Although
age-standardised rates of stroke mortality have de-
creased, the absolute number of people suffering stroke
annually, stroke survivors and overall stroke burden are
increasing [1]. Approximately 30 % of strokes occur in
individuals with a previous stroke and 50 % occur in
those with previous vascular events of any kind [2]. High
recurrence rates emphasize the importance of effective
preventive strategies and many population-based studies
have reported strong associations between numerous car-
diovascular risk factors and future stroke risk [2–4]. These
findings have informed the development of evidence-
based guidelines on stroke prevention [5, 6] which aim to
improve stroke outcomes.
The EUROASPIRE surveys [7–9] drew attention to the
continuing gap between standards set in guidelines on
secondary cardiovascular disease prevention (in patients
with coronary heart disease) and results achieved in clin-
ical practice. More recently, a stroke-specific module
retrospectively added to EUROASPIRE III concluded that
risk factor control after IS also requires improvement [10].* Correspondence: lindabrewer@beaumont.ie1Department of Geriatric & Stroke Medicine, Royal College of Surgeons in
Ireland (RCSI), Beaumont Hospital, Dublin 9, Ireland
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We report a prospective, multi-centre study which
assessed the extent to which evidence-based care was
provided to a sample of Irish patients admitted with IS,
as part of the Action on Secondary Prevention Interven-
tions and Rehabilitation in Stroke (ASPIRE-S) study.
This study reviewed three components of IS care follow-
ing discharge, including the adequacy of secondary pre-
vention, delivery of rehabilitative care and assessment of
ongoing rehabilitative needs. This analysis focuses on
the adequacy of secondary prevention at 6 months in
the ASPIRE-S cohort.
Methods
Study hospitals and patient recruitment
Patients aged 18 years and over with IS admitted to three
study hospitals were recruited between October 2011 and
September 2012. Ethical approval was granted from the
Medical Research Ethics Committees of participating
hospitals, Beaumont Hospital (BH), Mater Misericordiae
University Hospital (MMUH) and Connolly Hospital
(CHB). All three study hospitals are university-affiliated
teaching hospitals located in suburban (BH, CHB) and city
(MMUH) North Dublin locations, serving a combined
catchment area of over 750,000 people. The stroke popu-
lation in North Dublin has previously been characterised
by the North Dublin Population Stroke Study group
(NDPSS) [11, 12], which reported that over 90 % of acute
stroke cases are treated in an acute hospital. For the
ASPIRE-S study, hospital-based case ascertainment was
performed and a representative sample of patients with IS
was sought through review of daily admissions via emer-
gency departments and regular review of stroke consult
lists in each hospital. In advance of the commencement of
this study, the ASPIRE-S study team met with the stroke
teams at each site to explain the study inclusion and
exclusion criteria. Patients were considered eligible if
they had a World Health Organisation (WHO) de-
fined IS to include ICD-10 code 163 (cerebral infarc-
tion), including subcategories and were medically well
enough for participation.
Data collection at baseline
At recruitment, baseline details (including demographic
details, stroke subtypes using TOAST [13] and Bamford
[14] classifications and stroke risk factors) were collected
during a short structured bedside interview. For patients
who presented with severe stroke, their progress was
monitored over time and their participation was re-
quested once they were considered medically stable.
Every effort was made to include patients with severe
strokes, to avoid selection bias in favour of milder
strokes. All eligible patients were either approached in
person or (if already discharged) were phoned by a
member of the research team to discuss the study and to
obtain consent. Where capacity was inadequate, consent
to participate was obtained from the next of kin.
Patient interview and examination at six months
At 6 months post-stroke, patients were contacted for
follow-up at which point a detailed interview and exam-
ination were carried out, using standardised methods
and instruments. Most patients were reviewed in their
own home by a trained member of the research team,
with a minority of patients returning to a Clinical Re-
search Centre for assessment. All patients were re-
quested to fast from 8 pm on the preceding night for the
measurement of fasting blood tests at the visit. For the
purpose of this study, blood results were compared with
targets outlined in the European Guidelines on cardio-
vascular disease prevention in clinical practice (version
2012) [15] and (for diabetes) the American Diabetes As-
sociation 2013 Guidelines [16].
Anthropometrical and physiological measurements
Blood pressure
Following the measurement of arm circumference and the
application of an appropriately sized cuff, patients were
asked to sit comfortably with their arm relaxed and at
heart level. Blood pressure (BP) was measured using a
digital OMRON M6 (Intellisense™) Dual Check System. To
allow for comparison with EUROASPIRE [7], the first BP
measurement was recorded from the right arm, where pos-
sible. To assess for an important difference in BP between
arms, we also recorded BP from the left arm. Twenty-four
hour control of BP was assessed by applying a SpaceLabs
90207 monitor (SpaceLabs Inc, Wokingham, Berkshire,
UK) to the arm with the highest BP reading (where pos-
sible). This measured BP every 30 min by day (8 am to
10 pm) and every 60 min overnight (10 pm to 8 am).
Waist circumference/BMI
Waist circumference was measured by applying a stand-
ard flexible (Farla Medical, UK) measuring tape circum-
ferentially at the level of iliac crest and was compared
with WHO-defined targets (male target <94 cm; female
target <80 cm). Body weight was measured to the nearest
kilogram using a calibrated (EKS International, France)
mechanical weighing scales. Height was measured as the
maximum distance from the floor to the vertex of the
head and was recorded to the nearest centimetre. Body
mass index (BMI) was calculated using the formulation
weight (kg)/(height(m))2 and scores were categorised ac-
cording to Centres for Disease Control and Prevention
criteria [17].
Fasting blood tests
Patients had venous blood drawn to measure fasting glu-
cose (FG) and full lipid profiles including total cholesterol
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(TC), low density lipoprotein (LDL), high density lipopro-
tein (HDL) and triglycerides (TG). Glycosylated haemo-
globin (HbA1c) was measured in diabetic patients. All
blood samples were processed according to local protocols
governed by the Clinical Directorate of Laboratory Medi-
cine. For patients on warfarin, recent international nor-
malised ratio (INR) records (using patient-held booklets)
were reviewed to assess the adequacy of anti-coagulation.
Secondary preventive medications
A full list of medications was recorded by reviewing the
patient’s most recent prescription, pillbox or medication
containers.
Study governance and quality assurance
Study recruitment, follow-up and data management took
place under the supervision of the study steering com-
mittee. To ensure uniformity of method the first 10 6-
month visits were conducted in pairs (two of three
trained researchers) and thereafter all three researchers
conducted the follow-up assessments in the same man-
ner, using identical equipment. At regular intervals
throughout the study period, these assessments were
conducted in pairs to assure ongoing quality and uni-
formity of data collection.
Dataset and analysis
Descriptive statistics summarised and described the main
findings, including percentages for categorical variables,
and means and standard deviations (SD) for quantitative
data. Comparisons between subgroups were performed
using chi-squared analysis. Significance was calculated
at a level of p < 0.05. Data were analysed using STATA
(StataCorp 2013, Texas).
Results
Baseline characteristics
Three hundred two patients (mean age 69.1 years, stand-
ard deviation 12.8, range 21.8-94.9) with acute IS agreed
to participate. Demographic characteristics, stroke sub-
type and risk factors are outlined in Table 1. Overall, pa-
tients had a mean number of three risk factors (SD 1.7;
range 0-8), with almost all patients (240; 94 %) having at
least one risk factor for stroke at baseline.
Of 302 recruited patients, 46 patients (15 %) were
unavailable for assessment at 6 months. Reasons for
non-participation included patient refusal (n = 22), death
(n = 9), intercurrent serious illness (n = 6), uncontactable
(n = 5) and final diagnosis not stroke (n = 4). The re-
maining 256 patients participated in the follow-up assess-
ment. There were no documented cases of recurrent
stroke in the 6 month follow-up period for the 256 pa-
tients included.
Risk factors at six months
Fasting blood results
Blood was drawn from 232 patients (90.5 % of the co-
hort) to measure (FG) and lipid profiles. Blood was not
drawn due to patient refusal, unsuccessful phlebotomy
or failure to fast appropriately. Mean glucose level was
5.4 mmol/l (SD,1.35). HbA1c was measured in 91 %
(n = 46) of diabetic patients and the mean level was 6.7 %
(range 5.4–10.5; SD 0.99). Over one-quarter (28 %) of dia-
betic patients had an HbA1c ≥7 % and 29.4 % had FG
≥7 mmol/l. Amongst non-diabetic patients, 1.5 % had a
glucose level ≥7.0 mmol/L (diabetic range), 3.9 % had a re-
sult between 6.1 and 6.9 mmol/L (impaired fasting glucose
range – Europe) and 9.6 % had a result between 5.6 and
6.9 mmol/L (impaired fasting glucose range - American
Diabetes Association 2013) [18]. Mean lipid values (with
Table 1 Baseline demographic characteristics, stroke subtypes and risk factors (N = 302)
Demographic details N (%) Stroke subtype N (%) Risk factor N (%)
Age Bamford Hypertension 176 (57)
<65 103 (34) PACS 117 (38.7) Hypercholesterolemia 135 (46.9)
≥65 199 (66) LACS 81 (26.8) Atrial fibrillation 120 (38.3)
POCS 80 (26.5) Heart disease 91 (29.3)
Gender TACS 16 (5.3) Current smoking 84 (28.1)
Male 173 (57.3) Unclassifiable 8 (2.7) Previous TIA/stroke 76 (25)
Female 129 (42.7) Diabetes 60 (19.9)
TOAST Past smoking 53 (17.6)
Function (mRS) Cardioembolism 121 (40.1) Carotid disease 50 (16)
≤2 156 (51.7) Undetermined aetiology 84 (27.8) Alcohol excess 44 (14.5)
>3 146 (48.3) Large vessel atherosclerosis 51 (16.9) Depression 24 (8.2)
Small vessel disease 33 (10.9) Anxiety 20 (6.6)
Other determined aetiology 13 (4.3)
mRS modified rankin scale, PACS partial anterior circulation stroke, POCS posterior circulation, LACS lacunar stroke, TACS total anterior circulation stroke
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SD) were TC 4 mmol/l (0.99), LDL 2.1 mmol/l (0.88),
HDL 1.3 mmol/l (0.37) and TG 1.4 mmol/l (0.72). The
proportion of patients with fasting lipid results at target is
illustrated in Fig. 1.
Blood pressure
Office blood pressure The mean right arm systolic BP
was 148 mmHg (range 92–207; SD 22.2) and the mean
right arm diastolic BP was 81 mmHg (range 40–119; SD
12.8). Most patients did not reach recommended inter-
national targets for BP control (Table 2). Patients with a
diagnosis of hypertension at recruitment were less likely
to have their BP controlled at 6 months for each of the
targets outlined.
Blood pressure in right versus left arms A reading
was unavailable from both arms in 18 (7 %) patients. Of
patients with available readings bilaterally, 27 patients
(11.3 %) had a discrepancy of at least 20 mmHg between
systolic BP readings, an indicator of high risk for future
cardiovascular events [19].
Ambulatory blood pressure monitoring A 24 h ambu-
latory BP monitor was applied to 210 patients (82 % of
participants). Thirteen patients did not wear their moni-
tor overnight, likely due to device intolerance. Mean
24 h BP was 127/73 mmHg (systolic SD 15.6 & range
90–222; diastolic SD 9.6 & range 53–116). Daytime
mean was 128/74 (systolic SD 15.7 & range 91–222; dia-
stolic SD 10 & range 53–116) and nightime mean was
121/68 (systolic SD 15.1 & range 88–176; diastolic SD
9.7 & range 48–95). When compared with ESH Guide-
lines [20], more patients had their BP controlled by day
(target 135/85; 61.4 %) than by night (target 120/70;
43.6 %). Fifty-nine percent had overall 24 h BP control
at target (130/80).
Waist circumference and BMI
The mean waist circumference was 90 cm for females
(n = 95) and 97 cm for males (n = 142). Two-thirds
(67 %) had a waist circumference above target, including
79 % of females and 58 % of males. The mean BMI in
250 patients was 26.8 (range 17–48; SD 4.5). The pro-
portions of patients classified as ‘normal weight (18.5–
25 kg/m2)’, ‘overweight (25 – 30 kg/m2)’ and ‘obese
>30 kg/m2)’ were 32, 44 and 24 % respectively.
Smoking
The proportion of patients (M:F, 60:40) that smoked
6 months post stroke was 16.4 % (n = 42), compared
with 28 % (n = 72) at baseline.
Secondary preventive therapy
Antithrombotic medications
Almost all (249; 97.3 %) were on an anti-platelet and/or
anticoagulant medication. 160 patients (62.5 %) were on
anti-platelet medication and, of these, 36 patients (22.5 %)
were on dual anti-platelet therapy. Patients with carotid
artery disease were significantly more likely to be on dual
therapy (41 % versus 9 %, p < 0.001). 116 patients (45.3 %)
were on anti-coagulation therapy. Of those on Warfarin
(n = 100), the mean INR was 2.4 (1.2–3.7). 78 % had an
INR between 2 and 3. 14 % had a sub-therapeutic INR
and the remaining 8 % had a supra-therapeutic INR level.
One quarter of patients on anti-coagulation (n = 28; 24 %)
were also on anti-platelet therapy. Of patients with atrial
fibrillation (N = 97), 83.5 % (81/97) were on anticoagula-
tion at 6 months. The remaining patients (16/97; 16.5 %)
were not on anticoagulation due to a contra-indication
(12), patient too unwell (3) or patient refusal (1).
Lipid-lowering and anti-hypertensive medications
At follow-up, almost all patients (242; 94.5 %) were on
lipid-lowering therapy and three-quarters of patients
(N = 190; 74.2 %) were on anti-hypertensive therapy. Al-
most half of these patients were on single agent therapy,
with a further one-third (33 %) on dual anti-hypertensive
therapy. Remaining patients were on three (32; 16.8 %) or
four (5; 2.5 %) agents. Those most commonly prescribed
anti-hypertensives were beta blockers (N = 101, 39.5 %),
Fig. 1 Proportions of patients with lipid results at target at 6 months;
TC = total cholesterol (targets <5.0 mmol/L or <4.5 mmol/L (high-risk
target) [15]); HDL = high-density lipoprotein (target >1 in males and
>1.2 mmol/L in females); LDL = low-density lipoprotein (targets
<2.5 mmol/L or <1.8 mmol/L (high-risk target) [15]); TG = triglycerides
(target <1.7 mmol/L)
Table 2 Proportion of patients with BP at target (total N = 249)
Proportion of patients at target
BP target All patients With diagnosed
hypertension
No hypertension
diagnosed
P-value
≤130/80a 40 (16.1 %) 15 (10.5 %) 25 (23.6 %) p = 0.005
≤140/90b 91 (36.6 %) 43 (30.1 %) 48 (45.3 %) p < 0.05
≤135/85c 69 (27.7 %) 31 (21.7 %) 38 (35.6 %) p < 0.05
BP blood pressure
aTarget from European guidelines on cardiovascular disease protection
(high-risk patients) [15] & UK RCP National Clinical Guideline on Stroke [5] &
ESH Guideline 2007 [20] (after stroke)
bTarget used in EUROASPIRE studies [9]
cTarget in IHF guideline on stroke [6]; p-values apply to comparisons between
those with and without diagnosis of hypertension
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angiotensin-converting-enzyme inhibitors (N = 95, 37.1 %)
and calcium channel blockers (N = 55, 21.5 %). Although
patients on lipid-lowering therapy were more likely to
reach lipid targets, patients on anti-hypertensive ther-
apy had poor therapeutic control of blood pressure at
6 months (Table 3).
Discussion
This study reveals suboptimal control of many risk factors
post IS despite the availability of evidence-based therapies
and clear guidelines for secondary prevention. This cohort
was at high-risk for recurrent stroke, with prevalent base-
line risk factors, two-thirds over the age of 65 years, and
one-quarter having previous stroke. These findings raise
concern for health professionals and should prompt more
intensive management of risk factors.
Studies have shown an association between TC, LDL
and elevated TG with IS risk, especially among athero-
sclerotic and lacunar stroke subtypes [21]. Although mean
lipid levels recorded at 6 months were not excessively
high, many results were not at target. Only three-quarters
of our cohort had TC at target (<4.5 mmol/L) with a simi-
lar proportion (77 %) having LDL at target (<2.5 mmol/L).
However, these results compare favourably with those
from EUROASPIRE III (49 and 55 % respectively at target)
[8] and with results from the stroke-specific module of
EUROASPIRE III [10], likely due to the higher uptake of
lipid-lowering medications in our group. Outside the trial
setting, there is currently no published data available on
the adequacy of control of lipid levels specific to IS. Al-
though the optimal LDL level for secondary stroke pre-
vention is unclear, there is evidence from the SPARCL
study that tight control (<1.8 mmol/L; achieved by only
44 % of our cohort) reduces recurrent IS risk by one quar-
ter [22] and European guidelines now advise this target
for high-risk patients [15].
Diabetes is independently related to a greater risk of IS
(adjusted risk ratio, 2.26) [23]. For diabetic patients in
ASPIRE-S with suboptimal control (HbA1c ≥ 7, 28 %), it
is unknown (without access to patient notes at follow-
up) whether the treating physician opted for less strict
control in light of poorly tolerated hypoglycaemic epi-
sodes in some patients. Optimal target HbA1c levels in
diabetic patients still remain the subject of much debate,
and in most cases is individualised to particular patient
characteristics [24]. Only 1.5 % of non-diabetic patients
had FG ≥7 mmol/L. Four percent of patients had FG
within the impaired fasting glucose range (≥6.1 mmol/
L), but this rose to almost 10 % when the latest Ameri-
can Diabetes Association definition (≥5.6 mmol/L) was
applied [16]. Diagnoses were not made on the basis of a
single FG level in ASPIRE-S but it is known that early
dietary and lifestyle modifications can delay or prevent
the development of diabetes in patients with impaired
FG [25].
The prevalence of obesity in the developed world has
substantially increased over time [26]. Results from the
Physician’s Health Study reported a significant increase
in the relative risk of stroke with each unit increase of
BMI, independent of the effects of other stroke risk fac-
tors [27]. Over two-thirds of our cohort had a BMI of
≥25 kg/m2 with one quarter being classified as obese.
These levels are higher than those reported in the gen-
eral Irish population (overweight 39 % and obese 18 %)
[28] and likely contribute to other stroke/cardiovascular
risk factors such as hypertension, hyperlipidaemia and
diabetes. Two-thirds of participants had abdominal
obesity. These results suggest that a more active role for
sustained professional support and motivation in achiev-
ing successful weight reduction post stroke is needed, in-
cluding (repeated) clear advice on weight loss from
health professionals, which positively impacts on weight
Table 3 Therapeutic control of lipids and office blood pressure at follow-up
Proportion reaching target (%)
All patients On lipid-lowering medication No lipid-lowering treatment p-value
Lipid targetsa (mmol/l)
TC < 5.0 (200) 86.2 (196) 89.5 (4) 30.8 p < 0.001
TC < 4.5 (174) 75.0 (171) 78.1 (3) 23.1 p < 0.001
LDL < 2.5 (170) 76.9 (167) 79.5 (3) 27.3 p < 0.001
LDL < 1.8 (97) 43.9 (96) 45.7 (1) 9.1 p < 0.05
All patients On anti-hypertensive medication No anti-hypertensive medication p-value
BP targets (mmHg)
BP <140/90 (91) 36.6 (62) 33.2 (29) 46.8 P = 0.05
BP <135/85 (69) 27.7 (46) 24.6 (23) 37.1 P = 0.06
BP <130/80 (40) 16.1 (24) 12.8 (16) 25.8 p < 0.05
TC total cholesterol, LDL low-density lipoprotein, BP blood pressure
aEuropean Guidelines on cardiovascular disease prevention (version 2012) [15]
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loss behaviour [29]. Although multiple successful weight
reduction interventions are available, the ability of
patients post stroke to engage in vigorous exercise pro-
grammes may be limited. Studies to explore the effect-
iveness of interventions such as group education or
dietary changes for weight loss specifically after stroke
are limited. The first randomized-controlled trial to
evaluate the efficacy and safety of a weight management
intervention in stroke survivors using the System-
CHANGE™ approach is currently underway [30].
The INTERSTROKE study reported a doubling in the
risk for IS in current smokers (OR 2.09, 1.75–2.51) [3]. Al-
though smoking rates are reportedly decreasing over time
[2], 16 % were still smoking in our cohort at 6 months.
This reflects a smoking cessation rate of 41 % (compared
with 81 % in the Irish subgroup of EUROASPIRE III and
40 % in the stroke-specific module) [8, 10]. Although
physician advice to stop smoking is the most important
first step in the cessation process, this advice must be reit-
erated and reinforced by all health professionals [31]. Mul-
tiple pharmacotherapies for tobacco dependence have
been shown to increase smoking cessation rates [32], and
behavioural interventions can further increase the success
of smoking cessation [33].
Although the mean BP reading was not excessively ele-
vated, only 37 % of patients had BP ≤140/90 (similar to
EUROASPIRE stroke module; 38 %). Such poor control
of BP may reflect a lack of focus on secondary prevent-
ive initiatives for patients after stroke. The proportion at
target was lower amongst patients with a previous diag-
nosis of hypertension and amongst those on anti-
hypertensive therapy, reflecting the difficulty in treating
hypertension in clinical practice. Recent European guide-
lines [5, 15] suggest a lower BP target of ≤130/80 in pa-
tients after IS, where tolerated. Only 16 % of our cohort
achieved this target at 6 months and this proportion
dropped to 13 % amongst those on anti-hypertensive
therapy. Although these results reflect a single reading
in patients, they are a reminder that better management
of BP is required after IS including greater up-titration
of medication dosages and use of multiple medication
regimens in addition to lifestyle advice.
Ambulatory BP monitoring (reflecting multiple mea-
surements) is known to provide a more accurate meas-
ure of BP control [34]. This is one of the first studies to
describe ambulatory BP control post acute stroke and
results clearly demonstrate greater overall BP control,
compared with office readings. Better control of daytime
(versus nightime) readings may reflect the timing of ad-
ministration of antihypertensive medications (usually in
the morning) which impacts on circadian control [35]. It
may also reflect lack of attention placed by physicians
on nightime BP control. Nightime BP control has been
strongly linked to an increased risk of cardiovascular
disease in multiple studies, including the Dublin out-
come study of 5292 participants [36], which reported a
relative hazard ratio (for cardiovascular mortality) of
1.21 for each 10-mm Hg increase in nightime systolic
BP. This increased risk remained significant in older
patients [36, 37].
Most IS patients are prescribed a combination of car-
diovascular medications and this multi-factorial ap-
proach to secondary stroke prevention can result in a
substantial reduction (of up to 80 %) in future stroke
risk [38]. Although prescription rates of anti-thrombotic
and lipid-lowering medications in our cohort were high,
the prescription of anti-hypertensive medications ap-
peared suboptimal. Despite positive findings from the
pivotal PROGRESS study [39], a minority of patients in
ASPIRE-S were on dual ACE I and diuretic therapy.
However, a significant proportion of patients had hyper-
tension (58 %), atrial fibrillation (40 %) and/or heart dis-
ease (30 %) at baseline and were likely already established
on appropriate medications with anti-hypertensive effects
(such as beta-blockers or CCBs) prior to their stroke.
This study has many strengths including its prospect-
ive design, large sample size, high rate of follow-up, in-
hospital assessment of patients to verify eligibility for
inclusion and a standardised follow-up assessment at
6 months modelled on previous robust EUROASPIRE
surveys. There is little information in the stroke litera-
ture on the adequacy of secondary prevention after IS
and much of the findings from ASPIRE-S are therefore
novel. The recent EUROASPIRE III stroke-specific mod-
ule (including four countries) reported some comparable
findings but was retrospective, excluded IS patients over
80, had a broader follow-up period (6–36 months), used
self-reported definitions of vascular risk factors and un-
healthy lifestyle habits, did not include ambulatory BP
monitoring and had limited generalizability.
Limitations
The majority of the findings from ASPIRE-S are novel
within the Irish stroke setting (and further afield), but
there are some limitations to this study. Participants
were recruited over 12 months as a representative (not
consecutive) sample of ischaemic stroke patients in
North Dublin. However, no attempt was made to be se-
lective in any way and this cohort compares favourably
in many ways with that recruited in 2006 as part of the
North Dublin Population Stroke Study (NDPSS) [11].
Although the ASPIRE-S sample of three hospitals re-
flects the north Dublin population well, results may not
be representative of the population nationally. It may be
that the burden of cardiovascular risk factors is particu-
larly high in north Dublin. Higher prevalence of cardiovas-
cular risk factors has previously been linked with social
disadvantage [40, 41] and the north Dublin population
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includes several communities where social disadvantage is
common. Furthermore, although ASPIRE-S has a large
overall sample size, the statistical significance of some re-
sults may have been limited by small numbers within sub-
cohorts.
Conclusion
Given the strong evidence from consensus of expert
opinion for multi-dimensional risk factor management
in secondary stroke prevention [38] it is imperative that
tailored programmes of care (including risk factor con-
trol) be optimised. These should commence during the
patients’ hospital admission with seamless transfer to the
community. Over recent years there have been signifi-
cant advances in the standardisation of clinical guide-
lines for stroke care, however the introduction of
national stroke clinical guidelines alone is insufficient to
improve health care quality [42]. For efficacy, guidelines
should be incorporated into quality assurance cycles
with education programmes and local feedback [43]. Re-
sults from ASPIRE-S promote awareness of the import-
ance of ongoing surveillance of cardiovascular risk in
patients after IS and prompt further roll-out of similar
surveys internationally. This should encourage the estab-
lishment of local policies which support comprehensive,
professional, multi-disciplinary secondary preventive ini-
tiatives, accessible to all survivors of stroke.
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